Table 1 Roles of TRICs in regulating different inflammatory diseases
From: Tissue-resident immune cells: from defining characteristics to roles in diseases
Disease type | Specific disease | Cell type | Functions and mechanisms | Prognostic value | Ref. |
---|---|---|---|---|---|
Autoimmune disease | Psoriasis | CD8+TRM cell | Aggravate the skin inflammation by producing IL-17A | Negative | |
CCD4+TRM cell | Aggravate the skin inflammation by producing IL-22 | Negative | |||
Vitiligo | CD8+TRM cell | Aggravate the skin inflammation by producing TNF-α and IFN-γ | Negative | ||
RA | CD8+TRM cell | Promote joint injury and RA recurrence by recruiting circulating effector T cells | Negative | ||
Tissue-resident macrophages | Attenuate joint inflammation by constructing the intra-articular immunological barrier | Positive | |||
PsA | CD8+TRM cell | Promote joint injury and RA recurrence by producing IL-17A | Negative | ||
LN | CD8+TRM cell | Aggravate the renal inflammation by producing cytokines | Negative | ||
Tissue-resident macrophage | Promote kidney inflammation by recruiting monocytes, and producing cytokines that support the development of autoantibody-producing B cells | Negative | |||
ANCA-associated GN | CD8+TRM cell | Aggravate the renal inflammation by producing IL-17A | Negative | ||
MS | CD8+TRM cell | Aggravate the brain inflammation by producing cytokines and recruiting autoreactive T cells into the brain | Negative | ||
Microglia | Promote disease progression by producing proinflammatory cytokines or activating T cells | Negative | |||
Tissue-resident ILC3 | Attenuate neuroinflammation by inducing immune tolerance and inhibiting autoimmune T cells | Positive | |||
Tissue-resident MAIT cell | Promote disease progression by producing IL-17 | Negative | |||
SS | Tissue-resident macrophage | Promote disease progression by inducing proinflammatory T cell-mediated response | Negative | ||
CD8+TRM cell | Promote disease progression by producing TNF-α and IFN-γ | Negative | |||
Vasculitis | Tissue-resident macrophage | Promote disease development by inducing proinflammatory cell infiltration and cytokine production | Negative | ||
IBD | CD4+TRM cell | Aggregate the bowel inflammation by producing proinflammatory cytokines | Negative | ||
Tissue-resident MAIT cell | Aggravate the bowel inflammation by producing IL-17 | Negative | |||
Autoimmune cholangitis | CD8+TRM cell | Promote disease development by inducing the apoptosis of small bile duct epithelial cells and exhibit enhanced cytotoxicity | Negative | ||
Autoimmune hepatitis | CD8+TRM cell | \ | Negative | ||
Infectious disease | Influenza virus | trNK cell | Make immune responses to infected cells by producing cytokines and cytotoxic molecules | Positive | |
Tissue-resident macrophage | Defend against influenza infection by producing type I IFN | Positive | |||
Tissue-resident ILC1 | Defend against influenza infection by producing IFN-γ | Positive | |||
Tissue-resident Vγ9Vδ2 T cell | Defend against influenza infection by producing IFN-γ | Positive | |||
CD8+TRM cell | Defend against influenza infection by producing IFN-γ, TNF-α, and cytotoxic molecules | Positive | |||
BRM cell | Defend against influenza infection by producing enhanced antibodies | Positive | |||
HSV | CD4+TRM cell | Defend against HSV by producing IFN-γ and IL-4 | Positive | ||
Tissue-resident macrophage | Defend against HSV by producing proinflammatory cytokines | Positive | |||
CD4+TRM cell | Defend against HSV by producing IFN-γ | Positive | |||
CD8+TRM cell | Defend against influenza infection by producing IFN-γ, TNF-α, and cytotoxic molecules | Positive | |||
HIV | CD8+TRM cell | Defend against HIV by producing IFN-γ and CD107a | Positive | ||
CD8+TRM cell | Defend against HIV by enhancing local humoral immunity | Positive | |||
Tissue-resident macrophage | Aggravate HIV infection by supporting their persistence | Negative | |||
HBV | CD8+TRM cell | Defend against HBV by producing IFN-γ, TNF-α and IL-2 | Positive | ||
Tissue-resident γδT cell | Defend against HBV by producing IFN-γ | Positive | |||
MTB | Tissue-resident macrophage | Defend against MTB by initiating the innate immune response | Positive | ||
Tissue-resident γδT cell | Defend against MTB by producing IL-17 | Positive | |||
Tissue-resident ILC3 | Defend against MTB by initiating the innate immune response | Positive | |||
CD4+TRM cell | Defend against MTB by producing IL-17 | Positive | |||
Tissue-resident MAIT cell | Defend against MTB by producing IFN-γ and GZMB | Positive | |||
S. pneumoniae | Tissue-resident macrophage | Defend against S. pneumoniae by producing ROS and nitric oxide | Positive | ||
Tissue-resident macrophage | Reduce tissue inflammation by clearing apoptotic PMN during the S. pneumoniae infection | Positive | |||
Tissue-resident ILC3 | Defend against S. pneumoniae by producing IL-17 and IL-22 | Positive | |||
Tissue-resident γδT cell | Maintain tissue homeostasis during the resolution phase after infection | Positive | |||
BRM cell | Defend against S. pneumoniae by inducing humoral responses | Positive | |||
CD4+TRM cell | Defend against S. pneumoniae by producing IL-17 | Positive | |||
CD8+TRM cell | Defend against S. pneumoniae by producing IFN-γ | Positive | |||
S.aureus | Tissue-resident macrophage | Defend against S.aureus by producing ROS and nitric oxide | Positive | ||
CD4+TRM cell | Defend against S.aureus by producing IL-17 and IFN-γ | Positive | |||
Malaria | CD8+TRM cell | Eliminate parasite-infected hepatocytes by producing IFN-γ, TNF-α and IL-2 | Positive | ||
Leishmaniasis | CD4+TRM cell | Defend against parasites by producing IFN-γ and recruiting inflammatory monocytes and circulating T cells | Positive | ||
Tissue-resident macrophage | Produce anti-inflammatory cytokines and promote parasite growth | Negative | |||
Transplantation | Lung transplant | CD8+TRM cell | \ | Positive | |
Tissue-resident macrophage | Produce inflammatory cytokines to activate immune responses against allograft | Negative | |||
Skin transplant | TRM cell | \ | Negative | ||
Kidney transplant | CD8+TRM cell | \ | Negative |